АГРЕГАЦИЯ ТРОМБОЦИТОВ КАК МАРКЕР ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ АНТИАГРЕГАНТНОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА
Оригинальная статья
Дата публикации: марта 8, 2020
Ключевые слова
антиагрегантная терапия
оптическая трансмиссионная агрегатометрия
тромбоз стента
ишемическая болезнь сердца
оптическая трансмиссионная агрегатометрия
тромбоз стента
ишемическая болезнь сердца
Как цитировать
[1]
И. С. Пряхин, АГРЕГАЦИЯ ТРОМБОЦИТОВ КАК МАРКЕР ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ АНТИАГРЕГАНТНОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА, КМКВ, вып. 1, сс. 64-71, мар. 2020.
Аннотация
Изучалась возможность использования остаточной реактивности тромбоцитов (ОРТ) в качестве маркера эффективности и безопасности антиагрегантной терапии у пациентов с хроническими и острыми формами ишемической болезни сердца (ИБС). В исследование включено 102 пациента с различными формами ИБС и различными комбинациями антиагрегантной терапии. Пациентам проводилось тестирование функции тромбоцитов с помощью оптической трансмиссионной агрегатометрии. По результатам исследования данный метод может использоваться для персонификации терапии антиагрегантами и предотвращения ее ишемических и геморрагических осложнений.Литература
1.Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 14;39(3): 213-260. doi: 10.1093/eurheartj/ehx419.
2. Комаров А.Л., Панченко Е. Тестирование функции тромбоцитов для оценки риска тромбозов и кровотечений у больных ИБС, получающих антиагреганты. Российский кардиологический журнал 2015, 3(119): 25–34. doi: 10.15829/1560-4071-2015-3-25-34.
3. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А. Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ибс, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал. 2015, 3 (119): 25–34. doi: 10.15829/1560-4071-2015-03-25-34.
4. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F. et al. Low dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005; 118(7): 723-7. doi: 10.1016/j.amjmed.2005.03.041.
5. Li L., Li H.Y., Qiao R., Yu H.Y., Zeng H., Gao W. et al. Predictive value of antiplatelet resistance on early stent thrombosis in patients with acute coronary syndrome. Chin Med J (Engl). 2013; 126(4): 626-33. doi: 10.3760/cma.j.issn.0366-6999.20121384.
6. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Jukema J.W., Huisman M.V. Сlopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007; 154(2): 221-31. doi: 10.1016/j.ahj.2007.04.014
7. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T. at al. Comparison of platelet function tests in predicting clinical outcome in patients undergoingcoronary stent implantation. JAMA. 2010; 303(8): 754-62. doi: 10.1001/jama.2010.181.
8. Aradi D., Collet J.P., Mair J., Plebani M., Merkely B., Jaffe A.S. et al. Platelet function testing in acute cardiac care-is there a role for prediction or prevention of stent thrombosis and bleeding. Thromb Haemost, 2015, 113(2): 221-230. doi: 10.1160/TH14-05-0449.
9. Parodi G., Marcucci R., Valenti R., Gori A.M., Migliorini A., Giusti B. et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011; 306(11). 1215-23. doi:10.1001/jama.2011.1332.
10. Garabedian T., Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther. 2013; 3(1): 23-37.doi:10.3978/j.issn.2223-3652.2013.02.06.
11. Alfredsson J., Lindahl T.L., Gustafsson K.M., Janzon M., Jonasson L., Logander E. et al. Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). Thromb Res. 2015; 136(2): 335-40. doi: 10.1016/j.thromres.2015.05.021.
12. Valenti R., Cantini G., Marcucci R., Marrani M., Migliorini A., Carrabba N. et al. Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. Int J Cardiol. 2015; 201: 561-7. doi: 10.1016/j.ijcard.2015.04.052.
13. Stone G.W., Witzenbichler B., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (AdAPt-dEs): a prospective multicentre registry study. Lancet. 2013; 382: 614-23. doi: 10.1016/S0140-6736(13)61170-8.
14. D'Ascenzo F., Bollati M., Clementi F., Castagno D., Lagerqvist B., de la Torre Hernandez J.M. et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013; 167: 575-584. doi: 10.1016/j.ijcard.2012.01.080.
15. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., Cutlip D.E. N Engl J Med. Stent thrombosis in randomized clinical trials of drug-eluting stents. 2007; 356(10): 1020-1029. doi: 10.1056/NEJMoa067731.
16. Steg P.G., Harrington R.A., Emanuelsson H., Katus H.A., Mahaffey K.W., Meier B. et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013; 128(10): 1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589.
17. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K. et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost. 2008; 6: 54-61. doi: 10.1111/j.1538-7836.2007.02812.x.
18. Mega J.L., Simon T., Anderson J.L., Bliden K., Collet J-P., Danchin N. et al. CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis. Circulation. 2009; 120: S598–S599 doi: 10.1161/circ.120.suppl_18.S598-b.
19. Price M.J., Murray S.S., Angiolillo D.J., Lillie E., Smith E.N., Tisch R.L. et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the gIFt (genotype Information and Functional testing) study. J Am Coll Cardiol. 2012; 59(22): 1928-37. doi: 10.1016/j.jacc.2011.11.068.
20. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J. et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation. 2010; 121(4): 512-518. doi: 10.1161/CIRCULATIONAHA.109.885194.
21. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J. et al. Response to ticagrelor in clopidogrel nonresponders and responders and the effect of switching therapies: The RESPOND study. Circulation. 2010; 121: 1188-1199. doi: 10.1161/CIRCULATIONAHA.109.885194.
22. Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009; 30(14): 1753-1763. doi: 10.1093/eurheartj/ehp159.
23. Price M.J., Angiolillo D.J., Teirstein P.S., Lillie E., Manoukian S.V., Berger P.B. et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A time-dependent Analysis of the gauging Responsiveness With a Verifynow P2Y12 Assay: Impact on thrombosis and safety (gRAVItAs) trial. Circulation. 2011; 124: 1132–1137. doi: 10.1161/CIRCULATIONAHA.111.029165
24. Kirtane A.J.; Stuckey T.; Xu K., Witzenbichler B., Weisz G., Rinaldi M.J. et al.
Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study. J Am Coll Cardiol 2013; 62: B48–49. doi: 10.1016/j.jacc.2013.08.885
25. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol. 2011; 107(7): 995-1000. doi: 10.1016/j.amjcard.2010.11.025.
26. De la Torre-Hernández J.M., Alfonso F., Hernández F., Elizaga J., Sanmartin M., Pinar E. et al. Drug-Eluting Stent Thrombosis Results From the Multicenter Spanish Registry ESTROF. J Am Coll Cardiol. 2008; 51(10): 986-990. doi: 10.1016/j.jacc.2007.10.057.
27. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17). doi: 10.1001/jama.293.17.2126.
28. Yuan J., Xu G.M. Early and Late Stent Thrombosis in Patients with Versus Without Diabetes Mellitus Following Percutaneous Coronary Intervention with Drug-Eluting Stents: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2018; 18(6): 483-492. doi: 10.1007/s40256-018-0295-y.
29. Weisz G., Leon M.B., Holmes D.R., Kereiakes D.J., Popma J.J., Teirstein P.S. et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009; 53(17): 1488-1497. doi: 10.1016/j.jacc.2009.01.050.
30. Азаров A.А., Барбараш О.Л., Ганюков B.И., Барбараш Л.С. Предикторы ранних тромбозов стентов после экстренного чрескожного коронарного вмешательства у пациентов с острым инфарктом миокарда в сочетании с сахарным диабетом 2-го типа. Диагностическая и интервенционная радиология. 2012; 6(4); 43-50.
2. Комаров А.Л., Панченко Е. Тестирование функции тромбоцитов для оценки риска тромбозов и кровотечений у больных ИБС, получающих антиагреганты. Российский кардиологический журнал 2015, 3(119): 25–34. doi: 10.15829/1560-4071-2015-3-25-34.
3. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А. Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ибс, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал. 2015, 3 (119): 25–34. doi: 10.15829/1560-4071-2015-03-25-34.
4. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F. et al. Low dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005; 118(7): 723-7. doi: 10.1016/j.amjmed.2005.03.041.
5. Li L., Li H.Y., Qiao R., Yu H.Y., Zeng H., Gao W. et al. Predictive value of antiplatelet resistance on early stent thrombosis in patients with acute coronary syndrome. Chin Med J (Engl). 2013; 126(4): 626-33. doi: 10.3760/cma.j.issn.0366-6999.20121384.
6. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Jukema J.W., Huisman M.V. Сlopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007; 154(2): 221-31. doi: 10.1016/j.ahj.2007.04.014
7. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T. at al. Comparison of platelet function tests in predicting clinical outcome in patients undergoingcoronary stent implantation. JAMA. 2010; 303(8): 754-62. doi: 10.1001/jama.2010.181.
8. Aradi D., Collet J.P., Mair J., Plebani M., Merkely B., Jaffe A.S. et al. Platelet function testing in acute cardiac care-is there a role for prediction or prevention of stent thrombosis and bleeding. Thromb Haemost, 2015, 113(2): 221-230. doi: 10.1160/TH14-05-0449.
9. Parodi G., Marcucci R., Valenti R., Gori A.M., Migliorini A., Giusti B. et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011; 306(11). 1215-23. doi:10.1001/jama.2011.1332.
10. Garabedian T., Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther. 2013; 3(1): 23-37.doi:10.3978/j.issn.2223-3652.2013.02.06.
11. Alfredsson J., Lindahl T.L., Gustafsson K.M., Janzon M., Jonasson L., Logander E. et al. Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). Thromb Res. 2015; 136(2): 335-40. doi: 10.1016/j.thromres.2015.05.021.
12. Valenti R., Cantini G., Marcucci R., Marrani M., Migliorini A., Carrabba N. et al. Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. Int J Cardiol. 2015; 201: 561-7. doi: 10.1016/j.ijcard.2015.04.052.
13. Stone G.W., Witzenbichler B., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (AdAPt-dEs): a prospective multicentre registry study. Lancet. 2013; 382: 614-23. doi: 10.1016/S0140-6736(13)61170-8.
14. D'Ascenzo F., Bollati M., Clementi F., Castagno D., Lagerqvist B., de la Torre Hernandez J.M. et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013; 167: 575-584. doi: 10.1016/j.ijcard.2012.01.080.
15. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., Cutlip D.E. N Engl J Med. Stent thrombosis in randomized clinical trials of drug-eluting stents. 2007; 356(10): 1020-1029. doi: 10.1056/NEJMoa067731.
16. Steg P.G., Harrington R.A., Emanuelsson H., Katus H.A., Mahaffey K.W., Meier B. et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013; 128(10): 1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589.
17. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K. et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost. 2008; 6: 54-61. doi: 10.1111/j.1538-7836.2007.02812.x.
18. Mega J.L., Simon T., Anderson J.L., Bliden K., Collet J-P., Danchin N. et al. CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis. Circulation. 2009; 120: S598–S599 doi: 10.1161/circ.120.suppl_18.S598-b.
19. Price M.J., Murray S.S., Angiolillo D.J., Lillie E., Smith E.N., Tisch R.L. et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the gIFt (genotype Information and Functional testing) study. J Am Coll Cardiol. 2012; 59(22): 1928-37. doi: 10.1016/j.jacc.2011.11.068.
20. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J. et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation. 2010; 121(4): 512-518. doi: 10.1161/CIRCULATIONAHA.109.885194.
21. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J. et al. Response to ticagrelor in clopidogrel nonresponders and responders and the effect of switching therapies: The RESPOND study. Circulation. 2010; 121: 1188-1199. doi: 10.1161/CIRCULATIONAHA.109.885194.
22. Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009; 30(14): 1753-1763. doi: 10.1093/eurheartj/ehp159.
23. Price M.J., Angiolillo D.J., Teirstein P.S., Lillie E., Manoukian S.V., Berger P.B. et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A time-dependent Analysis of the gauging Responsiveness With a Verifynow P2Y12 Assay: Impact on thrombosis and safety (gRAVItAs) trial. Circulation. 2011; 124: 1132–1137. doi: 10.1161/CIRCULATIONAHA.111.029165
24. Kirtane A.J.; Stuckey T.; Xu K., Witzenbichler B., Weisz G., Rinaldi M.J. et al.
Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study. J Am Coll Cardiol 2013; 62: B48–49. doi: 10.1016/j.jacc.2013.08.885
25. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol. 2011; 107(7): 995-1000. doi: 10.1016/j.amjcard.2010.11.025.
26. De la Torre-Hernández J.M., Alfonso F., Hernández F., Elizaga J., Sanmartin M., Pinar E. et al. Drug-Eluting Stent Thrombosis Results From the Multicenter Spanish Registry ESTROF. J Am Coll Cardiol. 2008; 51(10): 986-990. doi: 10.1016/j.jacc.2007.10.057.
27. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17). doi: 10.1001/jama.293.17.2126.
28. Yuan J., Xu G.M. Early and Late Stent Thrombosis in Patients with Versus Without Diabetes Mellitus Following Percutaneous Coronary Intervention with Drug-Eluting Stents: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2018; 18(6): 483-492. doi: 10.1007/s40256-018-0295-y.
29. Weisz G., Leon M.B., Holmes D.R., Kereiakes D.J., Popma J.J., Teirstein P.S. et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009; 53(17): 1488-1497. doi: 10.1016/j.jacc.2009.01.050.
30. Азаров A.А., Барбараш О.Л., Ганюков B.И., Барбараш Л.С. Предикторы ранних тромбозов стентов после экстренного чрескожного коронарного вмешательства у пациентов с острым инфарктом миокарда в сочетании с сахарным диабетом 2-го типа. Диагностическая и интервенционная радиология. 2012; 6(4); 43-50.